JCA Pulse › JCA discontinued
JCA discontinuedSasanlimab: EU joint clinical assessment
Bladder cancer
This assessment was discontinued.
Overview
- Company
- Pfizer
- Therapy area
- Solid tumours · Bladder
- Indication
- Bladder cancer
- EMA validation
- 22 May 2025
- Discontinued
- 13 Feb 2026
- JCA assessor
- ZIN, The Netherlands
- Co-assessor
- Danish Medicines Council, Denmark
- Regulatory status
- MAA withdrawn; no EU authorisation.
- Reason
- The developer withdrew the marketing authorisation application.
Sources
Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.
From Evidaxia
- EU JCA dossiers and PICO scopingSupport from PICO scoping to the dossier
- JCA PICO scoping: process and preparationHow assessors set the scope
- EU JCA timelineEvery upcoming milestone
Also in Solid tumours
- Bifikafusp alfa / onfekafusp alfa (Nidlegy)Melanoma, neoadjuvant
- CamizestrantHR+/HER2− breast cancer, ESR1 switch
- CosibelimabCutaneous squamous cell carcinoma
- DaraxonrasibMetastatic pancreatic cancer
- Ensartinib (Gevalka)ALK-positive NSCLC
- FuzuloparibmCRPC, first line